BBA
VRTX icon

BLB&B Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

BLB&B Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Sell
506
-14
-3% -$6.21K 0.01% 261
2026
Q1 		$232K Sell
520
-8
-2% -$3.73K 0.01% 258
2025
Q4 		$239K Buy
528
+7
+1% +$3.02K 0.01% 260
2025
Q3 		$204K Buy
521
+7
+1% +$2.92K 0.01% 271
2025
Q2 		$229K Hold
514
– – 0.01% 254
2025
Q1 		$249K Sell
514
-12
-2% -$5.59K 0.01% 244
2024
Q4 		$212K Sell
526
-1
-0.2% -$464 0.01% 258
2024
Q3 		$245K Buy
527
+100
+23% +$48K 0.01% 251
2024
Q2 		$200K Buy
+427
New +$185K 0.01% 267

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BLB&B Advisors's VRTX Position: Q2 2026 in Review

BLB&B Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q2 2026, selling an estimated $6.21K and leaving 506 shares worth $251K. The position accounts for 0.01% of the portfolio, ranked #261.

BLB&B Advisors first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • BLB&B Advisors held 506 shares of Vertex Pharmaceuticals worth $251K as of Q2 2026.
  • BLB&B Advisors sold 14 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.21K.
  • Vertex Pharmaceuticals made up 0.01% of BLB&B Advisors's portfolio in Q2 2026, its #261 holding.
  • BLB&B Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on BLB&B Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.